Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual ( / ) Peroxisome Proliferator-Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A double-blind, randomized, pioglitazone-comparative study

Diabetes Care ◽  
2006 ◽  
Vol 29 (5) ◽  
pp. 1016-1023 ◽  
Author(s):  
D. M. Kendall ◽  
C. J. Rubin ◽  
P. Mohideen ◽  
J.-M. Ledeine ◽  
R. Belder ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Hdl Cholesterol ◽  
Peroxisome Proliferator ◽  
Double Blind ◽  
Peroxisome Proliferator Activated Receptor ◽  
Cholesterol Levels ◽  
Metformin Monotherapy ◽  
Receptor Activator

Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes

2015 ◽  
Vol 170 (1) ◽  
pp. 117-122 ◽  
Author(s):  
Erland Erdmann ◽  
Robert Califf ◽  
Hertzel C. Gerstein ◽  
Klas Malmberg ◽  
Luis Ruilope ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Receptor Activator

scholarly journals PPARγ2 Pro12Ala Polymorphism is Associated in Children With Traits Related to Susceptibility to Type 2 Diabetes

2021 ◽  
Vol 12 ◽  
Author(s):  
Claudia Vales-Villamarín ◽  
Olaya de Dios ◽  
Iris Pérez-Nadador ◽  
Teresa Gavela-Pérez ◽  
Leandro Soriano-Guillén ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Hdl Cholesterol ◽  
Recessive Model ◽  
Peroxisome Proliferator ◽  
Pro12ala Polymorphism ◽  
Peroxisome Proliferator Activated Receptor ◽  
Insulin Levels ◽  
Glucose And Lipid Metabolism ◽  
Treatment Of Obesity

Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated nuclear receptor that regulates glucose and lipid metabolism. Pharmacological activators of PPARγ are being used as a treatment of obesity related disorders such as dyslipidaemia and type 2 diabetes, but questions remain open regarding the effects of PPARγ on traits related to the development of type 2 diabetes. In our study, we have analyzed the relationship of the common variant Pro12Ala in the human PPARγ2 gene with the presence of obesity and with insulin, HOMA and lipid profile in a representative sample of 6-to 8-year-old children free from the confounding factors associated with adults. We found that Ala12Ala genotype was significantly more frequent in females with obesity than in those without obesity, with Ala12Ala carriers having significantly higher weight and body mass index (BMI), however the association disappeared when adjusting by leptin concentrations. The Ala12Ala genotype was associated with significantly higher HDL-cholesterol and apoA-I levels in males but not in females, independently of BMI. In a recessive model, in females, leptin levels appeared higher in Ala12Ala carriers. Although no apparent differences were observed in any sex when analyzing insulin levels and HOMA among genotypes without adjusting, lower insulin levels and lower HOMA appeared associated with Ala12Ala carriers when adjusting for BMI and leptin levels. In summary, our data showed that leptin seems to be having an effect on the association between the PPARγ2 Pro12Ala and BMI. Besides, after controlling for BMI and leptin, a protective effect of the Ala12Ala variant of the PPARγ2 Pro12Ala polymorphism on insulin sensitivity is evident already in prepubertal children.

Sign in / Sign up

Export Citation Format

Share Document